Their study revealed the critical role of exosomal PD-L1 in tumor cell immune evasion, suggesting that targeting exosomal PD-L1 may be a promising strategy for improving the clinical benefit of PD-1/PD-L1 checkpoint inhibitor therapy. This evidence concerns the gene CD274 and neoplasm.